Immunobiochem Corporation is a biotechnology company committed to addressing unmet medical need in oncology through research and development of novel, targeted biological therapeutics. ImmunoBiochem is headquartered in Ontario, Canada, and draws on the vast expertise of cancer researchers and clinicians located in the biomedical hub of downtown Toronto. ImmunoBiochem has pioneered a proprietary technology to address the challenge of cancer heterogeneity in solid tumors with its tumor microenvironment-targeted antibody-drug conjugates (ADCs). ADCs comprise a novel class of potentiated biological therapeutics, combining the targeting capabilities of monoclonal antibodies with the cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues. ADCs comprise an antibody component linked to a cytotoxic molecule via a stable linker that is uniquely engineered to deliver and release the cytotoxic payload in cancer cells. ImmunoBiochem's lead ADC candidates, IMB-202 and IMB-212, are in development for a number of solid malignancies, including the Triple-Negative Breast Cancer indication that is a significant unmet need with no biological treatment options currently available.